Press & Events
AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer
AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors
AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project
AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers
Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
AVEO Pharmaceuticals Appoints David Johnston as CFO
AVEO Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration
Archived Press
2013
AprilMarch
February
January
2012
DecemberNovember
October
September
August
July
June
May
April
March
February
January